Executive Vice President, Corporate Strategy, Alliances and Communications
In it for a passion to serve cancer patients.
Nancy brings deep knowledge of all phases of drug development and medical affairs to Seagen. As a clinical leader within our organization for more than a decade, she has made many important scientific contributions to all our programs, including driving the development strategies for ADCETRIS® (brentuximab vedotin) and TUKYSA® (tucatinib). Nancy also previously led our Global Medical Affairs and the Early-Stage Development functions.
Prior to joining Seagen, Nancy was a Senior Oncology Medical Scientist at GlaxoSmithKline and a Clinical Oncology Pharmacist at Seattle Cancer Care Alliance.
Nancy holds a Pharm.D. from the University of Washington and B.Sc. in Pharmaceutical Sciences from the University of British Columbia. She completed her residency in clinical pharmacy practice at the Vancouver General Hospital.
You are leaving Seagen
You are now leaving Seagen site. Seagen does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This resource link is for informational purposes only. Do you want to continue to the external site and leave Seagen.com?